AAAAAA
Results:
1-21
|
Results: 21
Authors:
WORTH LL
JAFFE N
BENJAMIN RS
PAPADOPOULOS NE
PATEL S
RAYMOND AK
JIA SF
RODRIGUEZ C
GANO J
GIANAN MA
KLEINERMAN ES
Citation: Ll. Worth et al., PHASE-II STUDY OF RECOMBINANT INTERLEUKIN-1-ALPHA AND ETOPOSIDE IN PATIENTS WITH RELAPSED OSTEOSARCOMA, Clinical cancer research, 3(10), 1997, pp. 1721-1729
Authors:
MURRAY JL
KLEINERMAN ES
JIA SF
ROSENBLUM MG
ETON O
BUZAID A
LEGHA S
ROSS MI
THOMPSON L
MUJOO K
RIEGER PT
SALEH M
KHAZAELI MB
VADHANRAJ S
Citation: Jl. Murray et al., PHASE-IA IB TRIAL OF ANTI-GD2 CHIMERIC MONOCLONAL-ANTIBODY-14.18 (CH14.18) AND RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (RHGM-CSF) IN METASTATIC MELANOMA/, Journal of immunotherapy with emphasis on tumor immunology, 19(3), 1996, pp. 206-217
Authors:
ASANO T
AN T
ZWELLING LA
TAKANO H
FOJO AT
KLEINERMAN ES
Citation: T. Asano et al., TRANSFECTION OF A HUMAN TOPOISOMERASE II-ALPHA GENE INTO ETOPOSIDE-RESISTANT HUMAN BREAST-TUMOR CELLS SENSITIZES THE CELLS TO ETOPOSIDE, Oncology research, 8(3), 1996, pp. 101-110
Authors:
ASANO T
AN T
JIA SF
KLEINERMAN ES
Citation: T. Asano et al., ALTERED MONOCYTE CHEMOTACTIC AND ACTIVATING FACTOR GENE-EXPRESSION INHUMAN GLIOBLASTOMA CELL-LINES INCREASED THEIR SUSCEPTIBILITY TO CYTOTOXICITY, Journal of leukocyte biology, 59(6), 1996, pp. 916-924
Authors:
ASANO T
AN TH
MAYES J
ZWELLING LA
KLEINERMAN ES
Citation: T. Asano et al., TRANSFECTION OF HUMAN TOPOISOMERASE II-ALPHA INTO ETOPOSIDE-RESISTANTCELLS - TRANSIENT INCREASE IN SENSITIVITY FOLLOWED BY DOWN-REGULATIONOF THE ENDOGENOUS GENE, Biochemical journal, 319, 1996, pp. 307-313
Authors:
GLASS RBJ
EFTEKHARI F
KLEINERMAN ES
JAFFE N
NACHMAN J
Citation: Rbj. Glass et al., OSTEOSARCOMA METASTATIC TO THE PANCREAS IN YOUNG-PATIENTS, Clinical Radiology, 51(4), 1996, pp. 293-294
Authors:
ASANO T
ZWELLING LA
AN T
MCWATTERS A
HERZOG CE
MAYES J
LOUGHLIN SM
KLEINERMAN ES
Citation: T. Asano et al., EFFECT OF TRANSFECTION OF A DROSOPHILA TOPOISOMERASE-II GENE INTO A HUMAN BRAIN-TUMOR CELL-LINE INTRINSICALLY RESISTANT TO ETOPOSIDE, British Journal of Cancer, 73(11), 1996, pp. 1373-1380
Authors:
HERZOG CE
ZWELLING LA
MCWATTERS A
KLEINERMAN ES
Citation: Ce. Herzog et al., EXPRESSION OF TOPOISOMERASE-II, BCL-2, AND P53 IN 3 HUMAN BRAIN-TUMORCELL-LINES AND THEIR POSSIBLE RELATIONSHIP TO INTRINSIC RESISTANCE TOETOPOSIDE, Clinical cancer research, 1(11), 1995, pp. 1391-1397
Authors:
KLEINERMAN ES
MEYERS PA
RAYMOND AK
GANO JB
JIA SF
JAFFE N
Citation: Es. Kleinerman et al., COMBINATION THERAPY WITH IFOSFAMIDE AND LIPOSOME-ENCAPSULATED MURAMYLTRIPEPTIDE - TOLERABILITY, TOXICITY, AND IMMUNE STIMULATION, Journal of immunotherapy with emphasis on tumor immunology, 17(3), 1995, pp. 181-193
Authors:
ASANO T
MCINTYRE BW
BEDNARCZYK JL
WYGANT JN
KLEINERMAN ES
Citation: T. Asano et al., LIPOSOMAL MURAMYL TRIPEPTIDE UP-REGULATES ADHESION MOLECULES ON THE SURFACE OF HUMAN MONOCYTES, Oncology research, 7(5), 1995, pp. 253-257
Authors:
KLEINERMAN ES
Citation: Es. Kleinerman, BIOLOGIC THERAPY FOR OSTEOSARCOMA USING LIPOSOME-ENCAPSULATED MURAMYLTRIPEPTIDE, Hematology/oncology clinics of North America, 9(4), 1995, pp. 927-938
Authors:
RISIN D
UMEZU Y
BALCH CM
KLEINERMAN ES
PIZZINI RP
PELLIS NR
Citation: D. Risin et al., IMPAIRMENT OF LYMPHOCYTE LOCOMOTION IN THE TUMOR MICROENVIRONMENT ANDTHE EFFECT OF SYSTEMIC IMMUNOTHERAPY WITH LIPOSOME-ENCAPSULATED MURAMYL-TRIPEPTIDE-PHOSPHATIDYLETHANOLAMINE, Cancer immunology and immunotherapy, 40(1), 1995, pp. 57-64
Authors:
KLEINERMAN ES
GANO JB
JOHNSTON DA
BENJAMIN RS
JAFFE N
Citation: Es. Kleinerman et al., EFFICACY OF LIPOSOMAL MURAMYL TRIPEPTIDE (CGP 19835A) IN THE TREATMENT OF RELAPSED OSTEOSARCOMA, American journal of clinical oncology, 18(2), 1995, pp. 93-99
Authors:
ASANO T
MATSUSHIMA K
KLEINERMAN ES
Citation: T. Asano et al., LIPOSOME-ENCAPSULATED MURAMYL TRIPEPTIDE UP-REGULATES MONOCYTE CHEMOTACTIC AND ACTIVATING FACTOR GENE-EXPRESSION IN HUMAN MONOCYTES AT THE TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL LEVELS, Cancer immunology and immunotherapy, 38(1), 1994, pp. 16-22
Authors:
FIDLER IJ
KLEINERMAN ES
Citation: Ij. Fidler et Es. Kleinerman, CLINICAL-APPLICATION OF PHOSPHOLIPID LIPOSOMES CONTAINING MACROPHAGE ACTIVATORS FOR THERAPY OF CANCER METASTASIS, Advanced drug delivery reviews, 13(3), 1994, pp. 325-340
Authors:
ASANO T
MCWATTERS A
AN T
MATSUSHIMA K
KLEINERMAN ES
Citation: T. Asano et al., LIPOSOMAL MURAMYL TRIPEPTIDE UP-REGULATES INTERLEUKIN-1-ALPHA, INTERLEUKIN-1-BETA, TUMOR-NECROSIS-FACTOR-ALPHA, INTERLEUKIN-6 AND INTERLEUKIN-8 GENE-EXPRESSION IN HUMAN MONOCYTES, The Journal of pharmacology and experimental therapeutics, 268(2), 1994, pp. 1032-1039
Authors:
ASANO T
KLEINERMAN ES
Citation: T. Asano et Es. Kleinerman, LIPOSOME-ENCAPSULATED MTP-PE - A NOVEL BIOLOGIC AGENT FOR CANCER-THERAPY, Journal of immunotherapy with emphasis on tumor immunology, 14(4), 1993, pp. 286-292
Authors:
FUJIMAKI W
ITOH K
AN T
GANO JB
ROSS MI
MANSFIELD PF
BALCH CM
AUGUSTUS LB
KARKEVITCH DD
JOHNSTON D
FIDLER IJ
KLEINERMAN ES
Citation: W. Fujimaki et al., CYTOKINE PRODUCTION AND IMMUNE CELL ACTIVATION IN MELANOMA PATIENTS TREATED WITH LIPOSOMAL MURAMYL TRIPEPTIDE (CGP-19835A LIPID), Cancer biotherapy, 8(4), 1993, pp. 307-318
Authors:
FIDLER IJ
KLEINERMAN ES
Citation: Ij. Fidler et Es. Kleinerman, THERAPY OF CANCER METASTASIS BY SYSTEMIC ACTIVATION OF MACROPHAGES - FROM THE BENCH TO THE CLINIC, Research in immunology, 144(4), 1993, pp. 284-287
Authors:
CURLEY SA
ROH MS
FEIG B
OYEDEJI C
KLEINERMAN ES
KLOSTERGAARD J
Citation: Sa. Curley et al., MECHANISMS OF KUPFFER CELL CYTOTOXICITY IN-VITRO AGAINST THE SYNGENEIC MURINE COLON ADENOCARCINOMA LINE MCA26, Journal of leukocyte biology, 53(6), 1993, pp. 715-721
Authors:
ASANO T
FUJIMAKI W
MCWATTERS A
AN TH
MATSUSHIMA K
KLEINERMAN ES
Citation: T. Asano et al., EFFECT OF ADRIAMYCIN ON LIPOSOMAL MURAMYL TRIPEPTIDES ABILITY TO UP-REGULATE MONOCYTE CYTOKINE EXPRESSION, Cancer immunology and immunotherapy, 37(6), 1993, pp. 408-411
Risultati:
1-21
|